Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era Abstract #1059

Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Aim(s): Herein, we reported the molecular characterization for 15 metastatic GEP-NET patients.
Materials and methods: We conducted the Ion AmpliSeq Cancer Hotspot Panel v2 (detecting 2,855 oncogenic mutations in 50 commonly mutated genes) and nCounter Copy Number Variation Assay (designed a 21-genes based on available targeted agents) as high throughput genomic platform in 14 patients with metastatic GEP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Seung Kim

To read results and conclusion, please login ...

Further abstracts you may be interested in

#882 Gene Expression Characterization of Gastroenteropancreatic Neuroendocrine Tumors [GEPNETS: Gastrointestinal and Pancreatic NETs (GINETs and pNETs)] and Their Correlation with Clinical Factors and Tumor Behavior
Introduction: GEP-NETs are a heterogenous group of tumors with different molecular backgrounds and clinical outcome.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: J A Díaz Pérez
#1297 Efficacy and Safety of Targeted Agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumor (NET): Single Center Experience
Introduction: As clinical features of NET are heterogeneous, the evaluation of real-world outcomes with everolimus and sunitinib are necessary.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Cho H, Kim K, Chang H M, ...
#643 Phase II Study of Pazopanib Monotherapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs) are still limited. The anti-angiogenic approach in metastatic pancreatic NETs has shown promising results.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Professor Young Suk Park
Authors: Park Y S, Ahn H K, Lee J, Choi J Y, ...
Keywords: Pazopanib, GEP-NETs
#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines
Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Tobias Hofving
#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS
Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Ana Paula Santos
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.